Trevi Therapeutics Reaches 75% of Enrollment Target for Phase 2B IPF Chronic Cough Study

MT Newswires Live

2024/12/12

Trevi Therapeutics (TRVI) said Thursday that enrollment in its phase 2b study of investigational therapy Haduvio in idiopathic pulmonary fibrosis with chronic cough has reached 75% of the targeted sample size of 160 patients.

The company said an independent data monitoring statistician reaffirmed the sample size of 160 IDF patients with chronic cough following a sample size re-estimation analysis, wherein 80 participants were treated with Haduvio at the highest dose of 108 mg twice daily for six weeks.

Topline results from the trial are still expected in H1 2025, the company added.

Trevi's stock surged 71% in recent Thursday premarket activity.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2490383056"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2490383056\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2490383056?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-12 21:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490383056","market":"sg","top_or_hot":-1,"title":"Trevi Therapeutics Reaches 75% of Enrollment Target for Phase 2B IPF Chronic Cough Study","media":"MT Newswires Live","content":"<html><body><p> Trevi <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TRVI) said Thursday that enrollment in its phase 2b study of investigational therapy Haduvio in idiopathic pulmonary fibrosis with chronic cough has reached 75% of the targeted sample size of 160 patients.</p><p>The company said an independent data monitoring statistician reaffirmed the sample size of 160 IDF patients with chronic cough following a sample size re-estimation analysis, wherein 80 participants were treated with Haduvio at the highest dose of 108 mg twice daily for six weeks.</p><p>Topline results from the trial are still expected in H1 2025, the company added.</p><p>Trevi's stock surged 71% in recent Thursday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Trevi Therapeutics Reaches 75% of Enrollment Target for Phase 2B IPF Chronic Cough Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrevi Therapeutics Reaches 75% of Enrollment Target for Phase 2B IPF Chronic Cough Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-12 21:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Trevi <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TRVI) said Thursday that enrollment in its phase 2b study of investigational therapy Haduvio in idiopathic pulmonary fibrosis with chronic cough has reached 75% of the targeted sample size of 160 patients.</p><p>The company said an independent data monitoring statistician reaffirmed the sample size of 160 IDF patients with chronic cough following a sample size re-estimation analysis, wherein 80 participants were treated with Haduvio at the highest dose of 108 mg twice daily for six weeks.</p><p>Topline results from the trial are still expected in H1 2025, the company added.</p><p>Trevi's stock surged 71% in recent Thursday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490383056","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490383056","pubTimestamp":1734009836,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Trevi Therapeutics  said Thursday that enrollment in its phase 2b study of investigational therapy Haduvio in idiopathic pulmonary fibrosis with chronic cough has reached 75% of the targeted sample size of 160 patients.The company said an independent data monitoring statistician reaffirmed the sample size of 160 IDF patients with chronic cough following a sample size re-estimation analysis, wherein 80 participants were treated with Haduvio at the highest dose of 108 mg twice daily for six weeks.Topline results from the trial are still expected in H1 2025, the company added.Trevi's stock surged 71% in recent Thursday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4139":"生物科技","LENZ":"Therapeutics","TRVI":"Trevi Therapeutics Inc."},"translate_title":"Trevi Therapeutics达到2B期IPF慢性咳嗽研究入组目标的75%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRVI":0.9,"LENZ":1},"content_text":"Trevi Therapeutics (TRVI) said Thursday that enrollment in its phase 2b study of investigational therapy Haduvio in idiopathic pulmonary fibrosis with chronic cough has reached 75% of the targeted sample size of 160 patients.The company said an independent data monitoring statistician reaffirmed the sample size of 160 IDF patients with chronic cough following a sample size re-estimation analysis, wherein 80 participants were treated with Haduvio at the highest dose of 108 mg twice daily for six weeks.Topline results from the trial are still expected in H1 2025, the company added.Trevi's stock surged 71% in recent Thursday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}